0001104659-19-047150.txt : 20190823
0001104659-19-047150.hdr.sgml : 20190823
20190823162647
ACCESSION NUMBER: 0001104659-19-047150
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190821
FILED AS OF DATE: 20190823
DATE AS OF CHANGE: 20190823
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MUELLER PETER
CENTRAL INDEX KEY: 0001256126
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38410
FILM NUMBER: 191049422
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioXcel Therapeutics, Inc.
CENTRAL INDEX KEY: 0001720893
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 821386754
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 555 LONG WHARF DRIVE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
BUSINESS PHONE: 203-643-8060
MAIL ADDRESS:
STREET 1: 555 LONG WHARF DRIVE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
4
1
a4.xml
4
X0306
4
2019-08-21
0
0001720893
BioXcel Therapeutics, Inc.
BTAI
0001256126
MUELLER PETER
C/O BIOXCEL THERAPEUTICS, INC.,
555 LONG WHARF DRIVE
NEW HAVEN
CT
06511
1
0
0
0
Common Stock
2019-08-21
4
P
0
1800
8.42
A
160120
D
Common Stock
2019-08-22
4
P
0
6646
8.83
A
166766
D
The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $8.29 to $8.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $8.43 to $9.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the SEC, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote.
/s/ Vimal D. Mehta, Attorney-in-Fact for Peter Mueller
2019-08-23